Effect of plasma protein binding-on in vivo activity and brain penetration of glycine/NMDA receptor antagonists

Journal of Medicinal Chemistry

Volumn 40, Issue 25, 1997, Pages 4053-4068

  Rowley, Michael ^a   Kulagowski, Janusz J ^a   Watt, Alan P ^a   Rathbone, Denise ^a   Stevenson, Graeme I ^a   Carling, Robert W ^a   Baker, Raymond ^a   Marshall, George R ^a   Kemp, John A ^a   Foster, Alan C ^a   Grimwood, Sarah ^a   Hargreaves, Richard ^a   Hurley, Catherine ^a   Saywell, Kay L ^a   Tricklebank, Mark D ^a   Leeson, Paul D ^a  

^a NEUROSCIENCE RESEARCH CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCINE RECEPTOR ANTAGONIST; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; WARFARIN;

ANTICONVULSANT ACTIVITY; ARTICLE; BLOOD BRAIN BARRIER; DRUG BINDING; DRUG BRAIN LEVEL; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; HUMAN;

ANIMALS; BLOOD PROTEINS; BLOOD-BRAIN BARRIER; BRAIN; EXCITATORY AMINO ACID ANTAGONISTS; MALE; MICE; PROTEIN BINDING; RATS; RECEPTORS, GLYCINE; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 15644370083     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm970417o     Document Type: Article

References (57)

1. Glave, W. R.; Hansch, C. Relationship between Lipophilic Character and Anesthetic Activity. J. Pharm. Sci. 1972, 61, 589-591.
2. (a) Hansch, C.; Bjorkroth, J. P.; Leo, A. J. Hydrophobicity and Central Nervous System Agents: On the Principle of Minimal Hydrophobicity in Drug Design. J. Pharm. Sci. 1987, 76, 663-687.
3. (b) Hansch, C.; Steward, A. R.; Anderson, S. M.; Bentley, D. The Parabolic Dependence of Drug Action upon Lipophilic Character as Revealed by a Study of Hypnotics. J. Med. Chem. 1968, 11, 1-11.
4. Gupta, S. P. QSAR Studies on Drugs Acting at the Central Nervous System. Chem. Rev. (Washington, D.C.) 1989, 89, 1765-1800.
5. Curry, S. H. Binding of Psychotropic Drugs to Plasma Protein and Its Influence on Drug Distribution. Clin. Pharmacol. Psychiatr. 1981, 213-223.
6. du Souich, P.; Verges, J.; Erill, S. Plasma Protein Binding and Pharmacological Response. Clin. Pharmacokinet. 1993, 24, 435-440.
7. Rolan, P. E. Plasma Protein Binding Displacement Interactions-Why Are They Still Regarded as Clinically Important? Br. J. Clin. Pharmacol. 1994, 37, 125-128.
8. Lindup, W. E. Plasma Protein Binding of Drugs-Some Basic and Clinical Aspects. Prog. Drug Metab. 1987, 10, 141-185.
9. Jezequel, S. G. Central Nervous System Penetration of Drugs: Importance of Physicochemical Properties. Prog. Drug Metab. 1992, 13, 141-178.
10. Jones, D. R.; Hall, S. D.; Jackson, E. K.; Branch, R. A.; Wilkinson, G. R. Brain Uptake of Benzodiazepines: Effect of Lipophilicity and Plasma Protein Binding. J. Pharmacol. Exp. Ther. 1988, 245, 816-822.
11. Chikale, E. G.; Ng, K. Y.; Burton, P. S.; Borchardt, R. T. Hydrogen Bonding Potential as a Determinant of the in Vitro and in Situ Blood-Brain Barrier Permeability of Peptides. Pharm. Res. 1994, 11, 412-419.
12. Stein, W. D. The Movement of Molecules Across Cell Membranes; Academic Press: New York, 1967; pp 65-91.
13. Seiler, P. Interconversion of Lipophilicities from Hydrocarbon/ Water Systems into the Octanol/Water System. Eur. J. Med. Chem. 1974, 9, 473-479.
14. 2 Receptor Histamine Antagonists. J. Med. Chem. 1988, 31, 656-671.
15. van der Waterbreemd, H.; Kansy, M. Hydrogen-Bonding Capacity and Brain Penetration. Chimia 1992, 46, 299-303.
16. Calder, J. A. D.; Ganellin, C. R. Predicting the Brain-Penetrating Capability of Histaminergic Compounds. Drug Des. Discovery 1994, 11, 259-268.
17. (a) Chadha, H. S.; Abraham, M. H.; Mitchell, R. C. Physico-chemical Analysis of the Factors Governing Distribution of Solutes between Blood and Brain. Bioorg. Med. Chem. Lett. 1994, 4, 2511-2516.
18. (b) Abraham, M. H.; Chadha, H. S.; Mitchell, R. C. Hydrogen Bonding. 33. Factors that Influence the Distribution of Solutes between Blood and Brain. J. Pharm. Sci. 1994, 83, 1257-1267.
19. Seelig, A.; Gottslich, R.; Devant, R. M. A Method to Determine the Ability of Drugs to Diffuse Through the Blood-Brain Barrier. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 68-72.
20. Leeson, P. D.; Iversen, L. L. The Glycine Site on the NMDA Receptor: Structure-Activity Relationships and Therapeutic Potential. J. Med. Chem. 1994, 37, 4053-4067.
21. Leeson, P. D.; Baker, R.; Carling, R. W.; Curtis, N. R.; Moore, K. W.; Williams, B. J.; Foster, A. C.; Donald, A. E.; Kemp, J. A.; Marshall, G. R. Kynurenic Acid Derivatives. Structure-Activity Relationships for Excitatory Amino Acid Antagonism and Identification of Potent and Selective Antagonists at the Glycine Site on the N-Methyl-D-aspartate Receptor. J. Med. Chem. 1991, 34, 1243-1252.
22. Leeson, P. D.; Carling, R. W.; Moore, K. W.; Moseley, A. M.; Smith, J. D.; Stevenson, G.; Chan, T.; Baker, R.; Foster, A. C.; Grimwood, S.; Kemp, J. A.; Marshall, G. R.; Hoogsteen, K. 4-Amido-2-carboxytetrahydroquinolines. Structure-Activity Relationships for Antagonism at the Glycine Site of the NMDA Receptor. J. Med. Chem. 1992, 35, 1954-1968.
23. Rowley, M.; Leeson, P. D.; Stevenson, G. I.; Moseley, A. M.; Stansfield, I.; Sanderson, I.; Robinson, L.; Baker, R.; Kemp, J. A.; Marshall, G. R.; Foster, A. C.; Grimwood, S.; Tricklebank, M. D.; Saywell, K. L. 3-Acyl-4-hydroxyquinolin-2(1H)-ones. Systemically Active Anticonvulsants Acting by Antagonism at the Glycine Site of the N-Methyl-D-Aspartate Receptor Complex. J. Med. Chem. 1993, 36, 3386-3396.
24. Kulagowski, J. J.; Baker, R.; Curtis, N. R.; Leeson, P. D.; Mawer, I. M.; Moseley, A. M.; Ridgill, M. P.; Rowley, M.; Stansfield, I.; Foster, A. C.; Grimwood, S.; Hill, R. G.; Kemp, J. A.; Marshall, G. R.; Saywell, K. L.; Tricklebank, M. D. 3'-(Arylmethyl)- and 3'-(Aryloxy)-3-phenyl-4-hydroxyquinoline-2(1H)-ones: Orally Active Antagonists of the Glycine Site on the NMDA Receptor. J. Med. Chem. 1994, 37, 1402-1405.
25. 5 L/mol. Kragh-Hansen, U. Relations between High-Affinity Binding Sites of Markers for Binding Regions on Human Serum Albumin. Biochem. J. 1985, 225, 629-638.
26. Breen, L.; Eastwood, F. W.; Ockman, T.; Rae, J. D.; Redwood, A. M. Formation of Aryl Acetic Acids, Arylacetamides and Aryldihydropyrroles from Aromatic Aldehydes. Aust. J. Chem. 1973, 26, 2221-2227.
27. Kappe, T.; Karem, A. S.; Stadibauer, W. Synthesis of Benzohalogenated-4-hydroxy-2(1H)-quinolones. J. Heterocycl. Chem. 1988, 25, 857-862.
28. Mawer, I. M.; Kulagowski, J. J.; Leeson, P. D.; Grimwood, S. Tetramic Acids as Novel Glycine Site Antagonists. Bioorg. Med. Chem. Lett. 1995, 5, 2643-2648.
29. Carling, R. W.; Leeson, P. D.; Moore, K. W.; Smith, J. D.; Moyes, C. R.; Mawer, I. M.; Thomas, S.; Chan, T.; Baker, R.; Foster, A. C.; Grimwood, S.; Kemp, J. A.; Marshall, G. R.; Tricklebank, M. D.; Saywell, K. L. 3-Nitro-3,4-dihydro-2(1H)-quinolones. Excitatory Amino Acid Antagonists Acting at the Glycine-Site NMDA and (RS)-α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid Receptors. J. Med. Chem. 1993, 36, 3397-3408.
30. Carling, R. W.; Leeson, P. D.; Moseley, A. M.; Smith, J. D.; Saywell, K.; Tricklebank, M. D.; Kemp, J. A.; Marshall, G. R.; Foster, A. C.; Grimwood, S. Anticonvulsant Activity of Glycine-Site NMDA Antagonists. 2. Trans 2-Carboxy-4-substituted tetrahydroquinolines. Bioorg. Med. Chem. Lett. 1993, 3, 65-70.
31. Curtis, N. R.; Kulagowski, J. J.; Leeson, P. D.; Mawer, I. M.; Ridgill, M. P.; Rowley, M.; Grimwood, S.; Marshall, G. R. Synthesis and SAR of Diiodotyrosine-Derived Glycine-Site N-Methyl-D-Aspartate Receptor Ligands. Bioorg. Med. Chem. Lett. 1996, 6, 1145-1150.
32. (a) Salituro, F. G.; Harrison, B. L.; Baron, B. M.; Nyce, P. L.; Stewart, K. T.; Kehne, J. H.; White, H. S.; McDonald, I. A. 3-(2-Carboxyindol-3-yl)propionic Acid-Based Antagonists of the N-Methyl-D-Aspartic Acid Receptor Associated Glycine Binding Site. J. Med. Chem. 1992, 35, 1791-1799.
33. (b) Rowley, M.; Leeson, P. D.; Grimwood, S.; Foster, A.; Saywell, K. 2-Carboxy Indolines and Indoles as Potential Glycine/NMDA Antagonists: Effect of Five-Membered Ring Conformation on Affinity. Bioorg. Med. Chem. Lett. 1992, 2, 1627-1630.
34. Di Fabio, R.; Capelli, A. M.; Conti, N.; Cugola, A.; Donati, D.; Feriani, A.; Gastaldi, P.; Gavirighi, G.; Hewkin, C. T.; Micheli, F.; Missio, A.; Mugnaini, M.; Pecunioso, A.; Quaglia, A. M.; Ratti, E.; Rossi, L.; Tedesco, G.; Trist, D. G.; Reggiani, A. Substituted Indole-2-carboxylates as in Vivo Potent Antagonists Acting at the Strychnine-Insensitive Glycine Binding Site. J. Med. Chem. 1997, 40, 841-850.
35. (a) Horner, L.; Schwenk, U.; Junghanns, E. Derivate des Chinoxalins als Isostere der Pteridine. Justus Liebigs Ann. Chem. 1953, 579, 212-234.
36. (b) Randle, J. C. R.; Guet, T.; Bobichon, C.; Moreau, C.; Curutchet, P.; Lambolez, B.; de Carvalho, L. P.; Cordi, A.; Lepagnol, J. M. Quinoxaline Derivatives: Structure-Activity Relationships and Physiological Implications of Inhibition of N-Methyl-D-aspartate and Non-N-Methyl-D-aspartate Receptor-Mediated Currents and Synaptic Potentials. Mol. Pharmacol. 1992, 41, 337-345.
37. Keana, J. F. W.; Kher, S. M.; Cai, S. X.; Dinsmore, C. M.; Glenn, A. G.; Guastella, J.; Huang, J.-C.; Ilyin, V.; Lu, Y.; Mouser, P. L.; Woodward, R. M.; Weber, E. Synthesis and Structure-Activity Relationships of Substituted 1,4-Dihydroquinoxaline-2,3-diones: Antagonists of N-Methyl-D-aspartate (NMDA) Receptor Glycine Sites and Non-NMDA Glutamate Receptors. J. Med. Chem. 1995, 38, 4367-4379.
38. Nagata, R.; Tanno, N.; Kodo, T.; Ae, N.; Yamaguchi, H.; Nishimura, T.; Antoku, F.; Tatsuno, T.; Kato, T.; Tanaka, Y.; Nakamura, M. Tricyclic Quinoxalinediones: 5,6-Dihydro-1H-pyrrolo[1,2,3-de]quinoxaline-2,3-diones and 6,7-1H,5H-Pyrido[1,2,3-de]quinoxaline-2,3-diones as Potent Antagonists for the Glycine Binding Site of the NMDA Receptor. J. Med. Chem. 1994, 37, 3956-3968.
39. Kappe, T.; Brandner, A.; Stadlbauer, W. Synthesis of Fused Benzofurans by Dehydration of Cyclic Phenyl-β-dicarbonyl Compounds. Monatsch. Chem. 1987, 118, 1177-1184.
40. 3H]-L-689,560, an antagonist for the glycine site of the N-methyl-D-aspartate receptor, to rat brain membranes. Mol. Pharmacol. 1992, 41, 923-930.
41. Kemp, J. A.; Foster, A. C.; Leeson, P. D.; Priestley, T.; Tridgett, R.; Iversen, L. L.; Woodruff, G. N. 7-Chlorokynurenic Acid is a Selective Antagonist at the Glycine Modulatory Site of the N-Methyl-D-Aspartate Receptor Complex. Proc. Natt. Acad. Sci. U.S.A. 1988, 85, 6547-6550.
42. Tricklebank, M. D.; Singh, L.; Oles, R. J.; Preston, C.; Iversen, S. D. The Behavioural Effects of MK-801: A Comparison with Antagonists Acting Noncompetitively and Competitively at the NMDA Receptor. Eur. J. Pharmacol. 1989, 167, 127-135.
43. Bos, O. J. M.; Remijn, J. P. M.; Fischer, M. J. E.; Wilting, J.; Janssen, L. H. M. Location and Characterisation of the Warfarin Binding Site of Human Serum Albumin. A Comparative Study of Two Large Fragments. Biochem. Pharmacol. 1988, 37, 3905-3909.
44. (b) Colangelo, P.; Chandler, M.; Blouin, R.; McNamara, P. Stereoselective Binding of Propranolol in the Elderly. Br. J. Clin. Pharmacol. 1989, 27, 519-522.
45. (a) Domenici, E.; Bertucci, C.; Salvadori, P.; Felix, G.; Cahagne, I.; Motellier, S.; Wainer, I. W. Synthesis and Chromatographic Properties of an HPLC Chiral Stationery Phase Based upon Human Serum Albumin. Chromatographia 1990, 29, 170-176.
46. (b) Domenici, E.; Bertucci, C.; Salvadori, P.; Motellier, S.; Wainer, I. W. Immobilized Serum Albumin: Rapid HPLC Probe of Stereoselective Protein-Binding Interactions. Chirality 1990, 2, 263-268.
47. (c) Noctor, T. G.; Felix, G.; Wainer, I. W. Stereochemical Resolution of Enantiomeric 2-Aryl Propionic Acid Non-Steroidai Antiinflammatory Drugs on a Human Serum Albumin Based High-Performance Liquid Chromatographic Chiral Stationary Phase. Chromatographia 1991, 31, 55-59.
48. (d) Noctor, T. G.; Wainer, I. W.; Hage, D. S. Allosteric and Competitive Displacement of Drugs from Human Serum Albumin by Octanoic Acid, as Revealed by High-Performance Liquid Chromatography, on a Human Serum Albumin-Based Stationary Phase. J. Chromatogr. 1992, 577, 305-315.
49. Noctor, T. G.; Diaz-Perez, M. J.; Wainer, I. W. Use of a Human Serum Albumin-Based Stationary Phase for High-Performance Liquid Chromatography as a Tool for the Rapid Determination of Drug-Plasma Protein Binding. J. Pharm. Sci. 1993, 82, 675-676.
50. Tricklebank, M. D.; Bristow, L. J.; Hutson, P. H.; Leeson, P. D.; Rowley, M.; Saywell, K.; Singh, L.; Tattersall, F. D.; Thorn, L.; Williams, B. J. The Anticonvulsant and Behavioural Profile of L-687,414, a Partial Agonist Acting at the Glycine Modulatory Site on the N-Methyl-D-aspartate (NMDA) Receptor Complex. Br. J. Pharmacol. 1994, 113, 729-736.
51. Takasato, Y.; Rapoport, S. I.; Smith, Q. R. An in Situ Brain Perfusion Technique To Study Cerebrovascular Transport in the Rat. Am. J. Physiol. 1984, 247, H484-H493.
52. Gratton, J. A.; Lightman, S. L.; Bradbury, M. W. Transport into Retina Measured by Short Vascular Perfusion in the Rat. J. Physiol. (London) 1993, 470, 651-663.
53. Measured as part of this work. See also ref 9.
54. 50 of 6 mg/kg when dosed po against NMDA-induced convulsions in the mouse. In our hands the compound is not active when dosed ip against audiogenic seizure in DBA/2 mouse at 10 mg/kg ip.
55. (a) Hansch, C.; Leo, A.; Unger, S. H.; Kim, K. H.; Nikaitani, D.; Lien, E. J. "Aromatic" Substituent Constants for Structure-Activity Correlations. J. Med. Chem. 1973, 16, 1207-1216.
56. (b) Rekker, R. F.; Mannhold, R. Calculaton of Drug Lipophilicity. The Hydrophobic Fragmental Constant Approach; VCH: Weinheim, Gemany, 1992.
57. Cai, S. X.; Kher, S. M.; Zhou, Z.-L.; Ilyin, V.; Espitia, S. A.; Tran, M.; Hawkinson, J. E.; Woodward, R. M.; Weber, E.; Keana, J. F. W. Structure-Activity Relationships of Alkyl- and Alkoxy-Substituted 1,4-Dihydroxyquinoxaline-2,3-diones: Potent and Systemically Active Antagonists for the Glycine Site of the NMDA Receptor. J. Med. Chem. 1997, 40, 730-738.